ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
The company impresses investors, but money’s running short.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
